BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

215 related articles for article (PubMed ID: 27165368)

  • 1. Malignant Peripheral Nerve Sheath Tumors.
    Durbin AD; Ki DH; He S; Look AT
    Adv Exp Med Biol; 2016; 916():495-530. PubMed ID: 27165368
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Expression of insulin-like growth-factor-1 receptor (IGF-1R) in peripheral nerve sheath tumors in neurofibromatosis type 1.
    Friedrich RE; Keiner D; Hagel C
    Anticancer Res; 2007; 27(4A):2085-90. PubMed ID: 17649826
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prognostic significance of AKT/mTOR and MAPK pathways and antitumor effect of mTOR inhibitor in NF1-related and sporadic malignant peripheral nerve sheath tumors.
    Endo M; Yamamoto H; Setsu N; Kohashi K; Takahashi Y; Ishii T; Iida K; Matsumoto Y; Hakozaki M; Aoki M; Iwasaki H; Dobashi Y; Nishiyama K; Iwamoto Y; Oda Y
    Clin Cancer Res; 2013 Jan; 19(2):450-61. PubMed ID: 23209032
    [TBL] [Abstract][Full Text] [Related]  

  • 4. NF1 deficiency causes Bcl-xL upregulation in Schwann cells derived from neurofibromatosis type 1-associated malignant peripheral nerve sheath tumors.
    Park HJ; Lee SJ; Sohn YB; Jin HS; Han JH; Kim YB; Yim H; Jeong SY
    Int J Oncol; 2013 Feb; 42(2):657-66. PubMed ID: 23292448
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Molecular characterization of permanent cell lines from primary, metastatic and recurrent malignant peripheral nerve sheath tumors (MPNST) with underlying neurofibromatosis-1.
    Fang Y; Elahi A; Denley RC; Rao PH; Brennan MF; Jhanwar SC
    Anticancer Res; 2009 Apr; 29(4):1255-62. PubMed ID: 19414372
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Targeted therapy for malignant peripheral nerve sheath tumor: translational research and clinical application].
    Liao ZC; Zhang C; Liu XY; Ren ZW; Xu J; Zhang CZ; Yang Y; Zhu Z; Yang JL
    Zhonghua Zhong Liu Za Zhi; 2019 Sep; 41(9):648-653. PubMed ID: 31550853
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Transposon Mutagenesis-Guided CRISPR/Cas9 Screening Strongly Implicates Dysregulation of Hippo/YAP Signaling in Malignant Peripheral Nerve Sheath Tumor Development.
    Vélez-Reyes GL; Koes N; Ryu JH; Kaufmann G; Berner M; Weg MT; Wolf NK; Rathe SK; Ratner N; Moriarity BS; Largaespada DA
    Cancers (Basel); 2021 Mar; 13(7):. PubMed ID: 33808166
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Malignant Peripheral Nerve Sheath Tumor: molecular pathogenesis and current management considerations.
    Grobmyer SR; Reith JD; Shahlaee A; Bush CH; Hochwald SN
    J Surg Oncol; 2008 Mar; 97(4):340-9. PubMed ID: 18286466
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ras-driven transcriptome analysis identifies aurora kinase A as a potential malignant peripheral nerve sheath tumor therapeutic target.
    Patel AV; Eaves D; Jessen WJ; Rizvi TA; Ecsedy JA; Qian MG; Aronow BJ; Perentesis JP; Serra E; Cripe TP; Miller SJ; Ratner N
    Clin Cancer Res; 2012 Sep; 18(18):5020-30. PubMed ID: 22811580
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Genetic and phenotypic characterization of tumor cells derived from malignant peripheral nerve sheath tumors of neurofibromatosis type 1 patients.
    Frahm S; Mautner VF; Brems H; Legius E; Debiec-Rychter M; Friedrich RE; Knöfel WT; Peiper M; Kluwe L
    Neurobiol Dis; 2004 Jun; 16(1):85-91. PubMed ID: 15207265
    [TBL] [Abstract][Full Text] [Related]  

  • 11. An ShRNA Screen Identifies MEIS1 as a Driver of Malignant Peripheral Nerve Sheath Tumors.
    Patel AV; Chaney KE; Choi K; Largaespada DA; Kumar AR; Ratner N
    EBioMedicine; 2016 Jul; 9():110-119. PubMed ID: 27333032
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeting of AKT/ERK/CTNNB1 by DAW22 as a potential therapeutic compound for malignant peripheral nerve sheath tumor.
    Li XX; Zhang SJ; Chiu AP; Lo LH; Huang J; Rowlands DK; Wang J; Keng VW
    Cancer Med; 2018 Sep; 7(9):4791-4800. PubMed ID: 30112810
    [TBL] [Abstract][Full Text] [Related]  

  • 13. MMP-13 and p53 in the progression of malignant peripheral nerve sheath tumors.
    Holtkamp N; Atallah I; Okuducu AF; Mucha J; Hartmann C; Mautner VF; Friedrich RE; Mawrin C; von Deimling A
    Neoplasia; 2007 Aug; 9(8):671-7. PubMed ID: 17786186
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Malignant peripheral nerve sheath tumors (MPNST) in neurofibromatosis type 1 (NF1): diagnostic findings on magnetic resonance images and mutation analysis of the NF1 gene.
    Friedrich RE; Kluwe L; Fünsterer C; Mautner VF
    Anticancer Res; 2005; 25(3A):1699-702. PubMed ID: 16033085
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Genetic basis of tumorigenesis in NF1 malignant peripheral nerve sheath tumors.
    Upadhyaya M
    Front Biosci (Landmark Ed); 2011 Jan; 16(3):937-51. PubMed ID: 21196210
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Vascular endothelial growth factor, basic fibroblast growth factor and epithelial growth factor receptor in peripheral nerve sheath tumors of neurofibromatosis type 1.
    Friedrich RE; Beer C; Glatzel M; Hagel C
    Anticancer Res; 2015 Jan; 35(1):137-44. PubMed ID: 25550544
    [TBL] [Abstract][Full Text] [Related]  

  • 17. International consensus statement on malignant peripheral nerve sheath tumors in neurofibromatosis.
    Ferner RE; Gutmann DH
    Cancer Res; 2002 Mar; 62(5):1573-7. PubMed ID: 11894862
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Preclinical in vivo evaluation of rapamycin in human malignant peripheral nerve sheath explant xenograft.
    Bhola P; Banerjee S; Mukherjee J; Balasubramanium A; Arun V; Karim Z; Burrell K; Croul S; Gutmann DH; Guha A
    Int J Cancer; 2010 Jan; 126(2):563-71. PubMed ID: 19634141
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Large-scale molecular comparison of human schwann cells to malignant peripheral nerve sheath tumor cell lines and tissues.
    Miller SJ; Rangwala F; Williams J; Ackerman P; Kong S; Jegga AG; Kaiser S; Aronow BJ; Frahm S; Kluwe L; Mautner V; Upadhyaya M; Muir D; Wallace M; Hagen J; Quelle DE; Watson MA; Perry A; Gutmann DH; Ratner N
    Cancer Res; 2006 Mar; 66(5):2584-91. PubMed ID: 16510576
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mechanisms underlying synergy between DNA topoisomerase I-targeted drugs and mTOR kinase inhibitors in NF1-associated malignant peripheral nerve sheath tumors.
    Ki DH; Oppel F; Durbin AD; Look AT
    Oncogene; 2019 Sep; 38(39):6585-6598. PubMed ID: 31444410
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.